Merck elects Isabel De Paoli as CSO
pharmafile | September 27, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | CSO, Merck, appointment
German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her current position as head of communications.
De Paoli will guide the new Group Strategy and Transformation arms of the business, integrating existing strategy, innovation and digitalisation across the company. She will report to Stefan Oschmann, CEO and chairman of the executive board.
“Over the past year, we’ve started to explore a variety of very promising innovation and digitalisation projects to deliver on our promise as a science and technology,” Oschmann commented. “Going forward, we will integrate those initiatives in a coherent strategy to ensure swift and successful implementation. Isabel De Paoli has built a strong track record in defining strategies and setting up organisations that yield efficient and effective returns – most recently in her role as head of group communications, successfully streamlining the organisation to support strategic objectives of our Healthcare, Life Science and Performance Materials businesses.”
De Paoli began her career as a consultant, working for the Boston Consulting Group before moving to private equity firm Permira. She joined Merck in 2006 as business development manager, chemicals, advancing to head of strategic planning, oncology in 2009. She held responsibility for group strategy from 2012 until 2015, when she was appointed head of communications.
Matt Fellows
Related Content
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …
